WALTHAM, Mass. Three new drugs for treating HIV from Gilead Sciences and J&J subsidiary Tibotec could have combined peak-year sales in the billions of dollars in several developed countries, according to a report by market research firm Decision Resources.
The report, titled “Human Immunodeficiency Virus,” predicted that through 2018, Gilead’s Quad, Tibotec’s rilpivirine and the combined drug rilpivirine, emtricitabine and tenofovir, made by Gilead and Tibotec, will have sales of more than $5 billion in the United States, United Kingdom, Germany, Italy, Spain and Japan.
“Gilead and Tibotec continue to make strong progress with their HIV programs,” Decision Resources therapeutic area director Danielle Dratyon said. “Gilead will bring the first-ever quadruple fixed-dose therapy — Quad — to the market, and Tibotec will bring a novel NNRTI — rilpivirine — to the market by 2011.”